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ABSTRACT 
Lysosomes are ubiquitous throughout all cell-types of the body and an inherited or 
acquired metabolic defect can potentially be causative of a disease phenotype as 
occurs in several lysosomal storage diseases (LSD). Fabry disease (FD) is one of the 
most prevalent LSD and is characterised by a deficient activity of the lysosomal 
enzyme alpha-galactosidase A (GLA) which is unable to exert its catabolic and 
clearance functions, thus leading to the accumulation of a specific type of ceramides— 
globotriaosylceramides (Gb3) in lysosomes. Many complications arise from FD, 
affecting manly the cardio-renal axis, the nervous system and skin. Since, this condition 
affects multi-tissues and organ-systems there is an unmet need to investigate how the 
molecular landscape is modulated after a single trigger caused by a mutation in GLA.  
INTRODUCTION 
Collectively, lysosomal storage diseases (LSD) are estimated to occurinone per five 
thousand live births and represent a group of 50 monogenetic disorders [1], affecting 
the normal function within vesicular structures of cells, in particular lysosomes, with 
relevant local and systemic metabolic consequences throughout body. 
Fabry disease (FD) (Figure 1A) is a recessive inherited disorder with a prevalence of 
one per forty thousand male live births and is caused by a single mutation of the 
lysosomal enzyme alpha-galactosidase A (GLA) in the X-chromosome [2]. This 
condition is manifested by impairment of the GLA activity resulting inintra-lysosomal 
accumulation of globotriaosylceramide (Gb3) and other glycolipid derivatives across 
many cell-types throughout the body. This phenomenon triggers a cascade of events, 
from disruption at the cellular-level of basic metabolic processes to activation of the 
immune-system followed by inflammatory response that ultimately leads to increased 
susceptibility of renal, cardiac, cerebrovascular, and skin complications [2,3]. 
The lysosomal accumulation of these ceramides in the vascular endothelium is known to 
cause low blood perfusion and is accepted as the main overlapping clinical 
parameter found in many FD manifestations affecting the renal-heart axis, nervous 
system, and skin [4,5]. Additionally, many FD patients exhibits vascular trauma and 
recurrent thrombotic episodes mostly due to lower plasma levels of thrombomodulin 
and elevated levels of plasminogen activator inhibitor [4]. Moreover, FD patients are 
at high-risk of stroke due to compromised endothelium-dependent vasodilation 
prompted by concurrently altered levels of nitric oxide and impaired activity of 
endothelial nitric oxide synthase [5]. Therefore, renal-heart failure and stroke remain 
the main cause of death among FD patients [6,7]. The life-span of FD patients can be 
extended by renal replacement therapy (e.g. dialysis, kidney transplantation) and by 
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enzyme replacement therapy through the clinical routine use of 
agalsidase-alpha and agalsidase-beta that mimic GLA 
activity, and the first is being consistently reported as an 
improver of the renal-cardiac function and cerebrovascular-
flow [3,8]. 
Gene-disease associations (GDA) databases such as DisGeNET 
[9] (Figure 1B) use supportive evidence from the literature and 
other disease databases to prioritise GDA. For instance, the 
best scored genes associated with FD are the following: GLA,  
NAT8, NOS3, IL6, CRP, VDR, NAIP, NOS2, ICAM1 and SELE. 
Regarding superimposed genes associated with cardiovascular 
conditions, this list is: AGT, involved in cholesterol transport 
(APOA1, APOA4, APOH), platelet activation (FGA, RNASE1) 
degranulation (SERPINA3, ALB, TF), HBA1 and 
RNASE2.Likewise, overlapping genes in FD concerning renal 
conditions are: IL1A, VCAM1, PON1, IL1B, TNF, AGT, NOS3, 
NAT8, MGP, and G6PD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CVD: Cardiovascular Diseases; RenDis: Renal Diseases; LySdis: Lysosomal Storage Diseases 
 
Previously we reported a systematic and systems biology-
derived approach in renal disease associated with FD [10], 
and found that perturbed biological processes are associated 
with activation of the acute inflammatory response, regulation 
of wound healing, extracellular matrix (ECM) remodelling, 
regulation of peptidase activity and cellular response to 
reactive oxygen species (ROS). Furthermore, the involvement of 
platelet activation (C1QTNF1, COL1A2, COL3A1, FGA, GP6, 
HSPB1, RNASE1, YWHAZ), initiated by binding of collagen 
(COL1A2, and COL3A1) to the platelet glycoprotein VI (GP6), 
leads to signal transduction through the involvement of FcR 
gamma-chain, the Src kinases and the linker for activation of T-
cell family member 1 (LAT) adapter protein, and consequently 
to the activation of phospholipase C gamma 2 (PLCG2) [11]. 
Ultimately, the process leads to the activation of the ligand-
binding function of integrin beta-3 to bind fibrinogen alpha 
chain (FGA). Subsequently platelet adhesion and aggregation 
are mediated, resulting in overall platelet spreading, granule 
secretion (degranulation), stabilisation of platelet adhesion and 
aggregation, and finally clot retraction. 
Moreover, we also described plateletgranule secretion with 
subsequent exocytosis of histamine and serotonin with further 
thrombus establishment at sites of vascular injury, a process 
relevant in the pathogenesis of many ischemic cardio- and 
cerebrovascular conditions [12,13]. Additionally, release of 
prostaglandin contributes to inflammation resolution and 
 
A B 
 
Figure 1: X-linked recessive inheritance in Fabry disease (A) with lysosomal accumulation of globotriaosylceramide (GL-3) and 
gene-disease associations superimposing (B) from DisGeNET. 
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promotes wound-healing important to restore tissue integrity 
and the earliest is known to be involved in smooth muscle 
contraction/relaxation and as well a potent inhibitor of 
platelet aggregation [14]. 
Additionally, the earlier event of disruption in the trade-off 
between production and degradation of extracellular matrix 
(ECM)throughout a long-term tissue injury can result in the 
deposition of ECM and consequently lead to pathological 
fibrosis [15] as observed in diabetic nephropathy and FD 
[16,17]. In a similar way, activation of many peptidases was 
also described and therefore exert direct proteolytic activity 
against ECM molecular entities or alternatively by activation of 
other proteases. For instance, proteolytic-antiproteolytic 
imbalance due to increased levels of collagens (COL11A1, 
COL1A2, COL3A1, COL4A2, and COL4A6) and augmented 
expression of cathepsins (CTSB) a main driver of proteolysis 
due to activation of a cascade of proteases which contrasts 
with over expression of several protease inhibitors (PI3, 
SERPINA3, SPINK1, SPINT1, ITIH4, and CSTB) [10]. 
Concomitantly, the association between altered states of ECM 
and overall FD severity could be indicative that ECM-turnover 
may play a role in FD pathogenesis [18,19]. 
Other known hallmarks in many cardiovascular diseases, such 
as enduring oxidative stress, was also reported in FD, for 
instance the activation of reactive oxygen species (ROS) 
response molecular elements. This is reinforced by the fact that 
Gb3 promotes oxidative stress and leads to an augmented 
expression in endothelial cells of many adhesion proteins [20]. 
In contrast, other studies report that, based on the molecular 
aspects of FD, many patients are more likely to resemble 
abnormalities related with renal insufficiency than to the 
underlying primary disease itself [21]. 
CONCLUSION 
A growing body of evidence in FD investigations supports the 
general hypothesis that an augmented profile of endothelial 
inflammation is earlier established in tandem with a hold-up of 
several phases of wound-healing, which leads to a long-lasting 
inflammatory phase. The pathogenicity of FD has long been 
solely credited to the long-term and continuous deposition of 
Gb3 in the vascular endothelium. Nevertheless, this initial 
metabolic defect is also known to trigger a cascade of 
molecular events that leads to earlier fibrosis, endothelial 
dysfunction and, with the advance of the disease, may promote 
recurrent thrombotic events during a patient’s life. 
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